Physicians appear more willing to prescribe Hospira’s Inflectra, a biosimilar version of J&J’s Remicade, to new patients in countries in Europe where it is available, but less inclined to switch patients already taking the brand. The company’s experience in Europe could offer lessons for manufacturers looking to bring biosimilars to market in the US.
After the European Medicines Agency approved Hospira Inc./Celltrion Inc.’s biosimilar version of Johnson & Johnson’s rheumatoid arthritis drug Remicade (infliximab) in 2013, Hospira began an intensive campaign to convince physicians to prescribe the drug, marketed under the brand name Inflectra.
Understanding full well the skepticism they would face being the first to launch a monoclonal antibody biosimilar in Europe, Hospira...
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.
